Hospital Pharmacy Europe - Industry News,

Click here

Sunday 26 May 2013 Register Login

You are here:

Suppliers Guide

New neurology product

Hospital Pharmacy Europe is assisting with a survey on messaging for a new neurology product. Click here

LATEST ISSUE

Contamination control and preparation of anticancer drugs, medicines reconciliation, Ruconest drug evaluation, ivacaftor for cystic fibrosis , oxycodone-naloxone prolonged-release tablets, IV chemotherapy, capsaicin in the treatment of severe neuropathic pain, alitretinoin in severe chronic hand eczema, Zyclara for actinic keratoses

Pharmacy Zone: Industry News

Magazine	Sponsored content
News	Video

Page:

1

Fri 24 May

Positive late-stage results for fasiglifam
Takeda’s recently announced positive late-stage results for new type 2 diabetes drug, fasiglifam, has prompted excitement...

Fri 24 May

Boehringer Ingelheim responds to FDA warning letter
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has issued a warning letter concerning its...

Tue 21 May

Tiotropium in symptomatic asthma patients
Tiotropium delivered by the Respimat Soft Mist Inhaler increases time to first severe exacerbation (p=0.03) and first episode of...

Tue 21 May

Phase III trial of regorafenib in patients with advanced liver cancer
Bayer HealthCare has announced that the company has started to enrol patients in an international Phase III trial to evaluate the...

Tue 21 May

Phase III results for afatinib and ninedanib
Boehringer Ingelheim has announced the upcoming presentation of data from 14 abstracts involving three of the company’s...

Mon 20 May

Vortioxetine clinical phase III data in depression
H Lundbeck A/S (Lundbeck) and partner Takeda Pharmaceutical Company Limited (Takeda) have announced that the companies will be...

Fri 17 May

Merck Serono: non-small cell lung cancer Phase III trial
Merck Serono, a division of Merck, Darmstadt, Germany, today announced detailed results from the randomised Phase III START*...

Fri 17 May

Oncology portfolio
Bayer HealthCare has announced that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets,...

Wed 1 May

Lundbeck on track to deliver on guidance
H. Lundbeck A/S (Lundbeck) reports first quarter revenue of DKK 4,576 million corresponding to an increase of 21%. Profit from...

Wed 24 Apr

Pre-clinical results on naproxcinod in models of muscular dystrophy
Nicox S.A. has announced promising pre-clinical results on naproxcinod, a CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating)...

Wed 24 Apr

Novartis delivers solid performance
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to...

Fri 19 Apr

Treatment with VX-661 and Ivacaftor result in improvements in lung function in CF
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 2 study of VX-661 and ivacaftor that showed...

Thu 18 Apr

Citizens' Innovation Funds could benefit UK growth
At a briefing earlier today hosted by the government's life sciences adviser, George Freeman MP at the House of Commons, sector...

Wed 17 Apr

First patient enrolled in global Phase III program evaluating Bayer's Amikacin Inhale
Bayer HealthCare has announced the successful enrolment of the first patient in a global Phase III program, INHALE, which will...

Tue 16 Apr

CPhI and PharmaEvolution.com to analyse pharma industry
CPhI Worldwide - a division of UBM Live - and its sister brand, Pharma Evolution (www.pharmaevolution.com) will introduce annual...

Mon 15 Apr

PDUFA action date for PA21
Following the submission of the New Drug Application (NDA) for PA21, the US Food and Drug Administration (FDA) has announced that...

Wed 10 Apr

Orion Diagnostica streamlining its operations in Finland
Orion Diagnostica Oy, a subsidiary of Orion Corporation focusing on diagnostic tests, has today given a negotiation proposal, as...

Wed 10 Apr

Orion invites analysts and media to Q1 conference
Orion will publish its Interim Report January-March 2013 on Tuesday, 23 April 2013 approximately at 12:00 Finnish time (EEST).

Wed 10 Apr

Lundbeck announces positive results for Brintellix™
H. Lundbeck A/S (Lundbeck) has announced positive results for the REVIVE study, a double-blind randomised study of...

Wed 10 Apr

New data on Selincro
H. Lundbeck A/S (Lundbeck) has announced the results of the revised analysis of the Phase III programme that formed the basis for...

Page:

1

Web design, hosting and programming by ModeZero